Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 4/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587150 | 0.95 | OPRK1 (0.33) | OPRK1IL1BP2RX7TP53ALDH1A1 | |
| SCHEMBL580791 | 0.90 | BRD4 (0.34) | IL1BP2RX7EPHX2 | |
| SCHEMBL581649 | 0.83 | GAA (0.32) | IL1BP2RX7ALDH1A1GAAMAPT | |
| SCHEMBL582194 | 0.83 | GAA (0.32) | IL1BP2RX7ALDH1A1GAAMAPT | |
| SCHEMBL3078365 | 0.83 | GAA (0.32) | IL1BP2RX7ALDH1A1GAAMAPT | |
| SCHEMBL1287102 | 0.79 | OPRK1 (0.42) | OPRK1TP53ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL586873 | 0.76 | IL1B (0.30) | IL1BP2RX7 | |
| SCHEMBL581808 | 0.74 | ALDH1A1 (0.39) | ALDH1A1POLBSMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL1287003 | 0.73 | OPRK1 (0.41) | OPRK1TP53ALDH1A1POLBGAA | |
| SCHEMBL582007 | 0.73 | PLG (0.41) | IL1BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | OPRK1 164/4885IL1B 4852/4885P2RX7 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.